Scarcity of COVID Shots Might Boost Demand among the Vaccine-Hesitant
Willingness is rising, even among skeptical groups, at a time when there are still not enough doses to go around -- Read more on ScientificAmerican.com
Willingness is rising, even among skeptical groups, at a time when there are still not enough doses to go around -- Read more on ScientificAmerican.com
Uptake by patients and physicians has been low in the U.S., even though some therapies have been authorized for months -- Read more on ScientificAmerican.com
Trials of all three vaccines came up with different efficacy numbers, but all offer crucial protection in this health emergency -- Read more on ScientificAmerican.com
Trusted messengers and repeated reminders can overcome hesitancy, social science shows -- Read more on ScientificAmerican.com
Scientific American talked to scientists about everything from what efficacy means to protection against the new coronavirus variants -- Read more on ScientificAmerican.com
Vaccine makers are designing follow-up shots, based on new mutations, to keep the disease at bay -- Read more on ScientificAmerican.com
As more coronavirus vaccines are rolled out, researchers are learning about the extent and nature of side effects -- Read more on ScientificAmerican.com
Antibiotics abound, but virus-fighting drugs are harder to come by. Fortunately, scientists are getting better at making and finding them -- Read more on ScientificAmerican.com
Some evidence indicates that short waits are safe, but there is a chance that partial immunization could help risky new coronavirus variants to develop -- Read more on ScientificAmerican.com
The scantness of available data leaves the decision up to the individual and their doctors, though benefits can outweigh risks in some cases -- Read more on ScientificAmerican.com
The scantness of available data leaves the decision up to the individual and their doctors, though benefits can outweigh risks in some cases -- Read more on ScientificAmerican.com
It will not be an easy task -- Read more on ScientificAmerican.com
Pfizer and Moderna may be the first past the post, but a slew of other candidates could address gaps in efficacy, production or distribution -- Read more on ScientificAmerican.com
Lessons from other viruses show that even if vaccines don’t completely stop disease spread, they can still successfully contain it -- Read more on ScientificAmerican.com
With a vaccine in limited availability, many still need medicines to keep the virus at bay -- Read more on ScientificAmerican.com
Scientists are debating whether to delay, skip or halve doses. But untested tweaks could shake public confidence -- Read more on ScientificAmerican.com